Analysts Remain Encouraged By Bellicum Pharma's Progress

Analyst Reni Benjamin termed the update on the company's ongoing phase 1/2 study of BPX-501 at the EHA as incrementally positive. The analyst said he continues to be encouraged that the treatment benefits were largely maintained, as more patients were treated and followed for a longer time.

"More importantly, the results achieved by BPX-501 appear to be better than those seen with some other transplant approaches in historical studies," the analyst added.

Raymond James said it continues to recommend shares of Bellicum to long-term oriented, risk-tolerant investors on the following premises:

• Continued progress made with the BPX-501 program both in the U.S. and EU.
• The advancement of the CAR T/TCR franchise through clinical development.
• Proforma net cash position of $145 million.

As such, Raymond James maintains its Outperform rating on the shares of Bellicum.